Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Large Drop in Short Interest

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 5,030,000 shares, a decrease of 6.0% from the January 15th total of 5,350,000 shares. Approximately 9.1% of the company’s shares are short sold. Based on an average trading volume of 882,500 shares, the short-interest ratio is currently 5.7 days.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ:AGIO opened at $34.02 on Thursday. Agios Pharmaceuticals has a 52-week low of $26.19 and a 52-week high of $62.58. The company has a 50 day moving average of $34.45 and a two-hundred day moving average of $43.14. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 3.00 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, equities analysts anticipate that Agios Pharmaceuticals will post -6.66 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AGIO. Venturi Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $33,000. GF Fund Management CO. LTD. acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $39,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $53,000. Sterling Capital Management LLC grew its position in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 1,587 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.